Top 20 Best Selling Drugs of 2012
Genetic Engineering and Biotechnology News (GEN)
Note I also added this compilation to the "Facts and Figures" page (housed on the Education menu above) - check out the rest of the informational links for the biotech enthusiast.
Importance of a Drug's "Risk-Benefit" Profile Eludes Former FDA Commissioner
Forbes - John LaMattina
I agree with this author and also thought the referenced article was pretty absurd in numerous ways
A Bright Future for Orphan Drug Indications
Biotech Now via BioMedTracker
Unreported Side Effects of Drugs Found Using Internet Data, Study Finds
New York Times
Equal parts "power of The Google" and limitations of the current physician adverse events reporting system.
Sangamo's HIV Gene Therapy Is A Valuation Prop, Nothing More
The Street - Adam Feuerstein
I agree with this article - you can probably comb back through my 5000+ tweets and not find a single positive comment about SGMO. Way over-hyped and no prospect of paying off anytime soon. Think ISIS a decade ago.
A Chat With Oxford Nanopore's Clive Brown at AGBT 2013
Pathogens: Genes and Genomes Blog
Amusing account re the upstart genome sequencing company that splashed onto the scene a year ago at AGBT making promises that seemed obviously impossible to live up to. Stunningly, reality won and they have not yet produced any data or made the "MinION" product available. Oxford is a privately held competitor to PACB ILMN LIFE GNOM.